The role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes

Przeglad Gastroenterologiczny

Volumn 9, Issue 2, 2014, Pages 69-76

  Adamska, Edyta ^a   Ostrowska, Lucyna ^a   Goŕska, Maria ^a   Kreţowski, Adam ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Diabetes; Gut hormones; Obesity

Indexed keywords

CHOLECYSTOKININ; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN; OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY;

BRAIN STEM; FEEDING BEHAVIOR; FOOD INTAKE; HUMAN; HUNGER; HYPOTHALAMUS; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; REVIEW; SATIETY;

EID: 84901004671     PISSN: 18955770     EISSN: 18974317     Source Type: Journal    
DOI: 10.5114/pg.2014.42498     Document Type: Review

References (82)

1. Bray GA. Autonomic and endocrine factors in the regulation of food intake. Brain Res Bull 1985; 14: 505-10. (Pubitemid 16239686)
2. Das UN. Obesity: genes, brain, gut, and environment. Nutrition 2010; 26: 459-73.
3. Lenard NR, Berthoud HR. Central and peripheral regulation of food intake and physical activity: pathways and genes. Obesity (Silver Spring) 2008; 16 (Suppl. 3): S11-22.
4. Coll AP, Farooqi IS, O'Rahilly S. The hormonal control of food intake. Nutrition 2007; 20: 251-62. (Pubitemid 46574977)
5. King BM. The rise, fall, and resurrection of the ventromedial hypothalamus in the regulation of feeding behavior and body weight. Physiol Behav 2006; 87: 221-44. (Pubitemid 43188818)
6. Suzuki K, Simpson KA, Minnion JS, et al. The role of gut hormones and the hypothalamus in appetite regulation. Endocr J 2010; 57: 359-72.
7. Kojima M, Hosoda H, Date Y. Ghrelin is a growth hormone releasing acylated peptide from stomach. Nature 1999; 402: 656-60. (Pubitemid 129516334)
8. Wren AM, Small CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000; 141: 4325-8.
9. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623-30. (Pubitemid 34755670)
10. Callahan HS, Cummings DE, Pepe MS, et al. Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans. J Clin Endocrinol Metab 2004; 89: 1319-24. (Pubitemid 38368431)
11. Foster-Schubert KE, Overduin J, Prudom CE, et al. Acyl and total ghrelin are suppressed strongly by ingested proteins, weakly by lipids, and biphasically by carbohydrates. J Clin Endocrinol Metab 2008; 93: 1971-9. (Pubitemid 351656546)
12. Stock S, Leichner P, Wong AC, et al. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. J Clin Endocrinol Metab 2005; 90: 2161-8. (Pubitemid 40586256)
13. Korek E, Krauss H, Gibas-Dorna M, et al. Fasting and postprandial levels of ghrelin, leptin and insulin in lean, obese and anorexic subjects. Prz Gastroenterol 2013; 8: 383-9.
14. Mittelman SD, Klier K, Braun S, et al. Obese adolescents show impaired meal responses of the appetite-regulating hormones ghrelin and PYY. Obesity (Silver Spring) 2010; 18: 918-25.
15. Muccioli G, Tschöp M, Papotti M, et al. Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol 2002; 440: 235-54. (Pubitemid 34458027)
16. Briggs DI, Andrews ZB. Metabolic status regulates ghrelin function on energy homeostasis. Neuroendocrinology 2011; 93: 48-57.
17. Andrews ZB, Liu ZW, Walllingford N, et al. UCP2 mediates ghrelin's action on NPY/AGRP neurons by lowering free radicals. Nature 2008; 454: 846-51.
18. Shearman LP, Wang SP, Helmling S, et al. Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 2006; 147: 1517-26. (Pubitemid 43244387)
19. Wren AM, Small CJ, Abbott CR, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes 2001; 50: 2540-7. (Pubitemid 33642772)
20. Gibbs J, Young RC, Smith GP. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 1973; 84: 488-95.
21. Buffa R, Solcia E, Go VL. Immunohistochemical identification of the cholecystokinin cell in the intestinal mucosa. Gastroenterology 1976; 70: 528-32.
22. Liddle RA, Goldfine ID, Rosen MS, et al. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 1985; 75: 1144-52. (Pubitemid 15087139)
23. Moran TH, McHugh PR. Cholecystokinin suppresses food intake by inhibiting gastric emptying. Am J Physiol 1982; 242: 491-7.
24. Rehfeld JF, Sun G, Christensen T, et al. The predominant cholecystokinin in human plasma and intestine is cholecystokinin-33. J Clin Endocrinol Metab 2001; 86: 251-8. (Pubitemid 32109804)
25. Beinfeld MC, Meyer DK, Brownstein MJ. Cholecystokinin in the central nervous system. Peptides. 1981; 2 (Suppl. 2): 77-9. (Pubitemid 12118287)
26. Moran TH, Robinson PH, Goldrich MS, et al. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res 1986; 362: 175-9. (Pubitemid 16185437)
27. Wank SA, Pisegna JR, de Weerth A. Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proc Natl Acad Sci USA 1992; 89: 8691-5.
28. Melville LD, Smith GP, Gibbs J. Devazepide antagonizes the inhibitory effect of cholecystokinin on intake in sham-feeding rats. Pharmacol Biochem Behav 1992; 43: 975-7.
29. Moran TH, Katz LF, Plata-Salaman CR, et al. Disordered food intake and obesity in rats lacking cholecystokinin A receptors. Am J Physiol 1998; 274: R618-25.
30. Kopin AS, Mathes WF, McBride EW, et al. The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. J Clin Invest 1999; 103: 383-91. (Pubitemid 29069988)
31. Kissileff HR, Pi-Sunyer FX, Thornton J, et al. C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 1981; 34: 154-60. (Pubitemid 11186304)
32. Smith GP, Jerome C, Cushin BJ, et al. Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. Science 1981; 213: 1036-7.
33. Deutsch JA, Hardy WT. Cholecystokinin produces bait shyness in rats. Nature 1977; 266: 196.
34. Swerdlow NR, van der Kooy D, Koob GF, et al. Cholecystokinin produces conditioned place-aversions, not place-preferences, in food-deprived rats: evidence against involvement in satiety. Life Sci 1983; 32: 2087-93. (Pubitemid 13135551)
35. Mosher JT, Birkemo LS, Johnson MF, et al. Sulfated cholecystokinin (26-33) induces mild taste aversion conditioning in rats when administered by three different routes. Peptides 1998; 19: 849-57. (Pubitemid 28312282)
36. West DB, Greenwood MR, Marshall KA, et al. Lithium chloride, cholecystokinin and meal patterns: evidence that cholecystokinin suppresses meal size in rats without causing malaise. Appetite 1987; 8: 221-7.
37. Matson CA, Ritter RC. Long-term CCK-leptin synergy suggests a role for CCK in the regulation of body weight. Am J Physiol 1999; 276: R1038-45. (Pubitemid 29214175)
38. West DB, Fey D, Woods SC. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol 1984; 246: R776-87. (Pubitemid 14111438)
39. Crawley JN, Beinfeld MC. Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 1983; 302: 703-6. (Pubitemid 13120271)
40. Zwirska-Korczala K, Konturek SJ, Sodowski M, et al. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome. J Physiol Pharmacol 2007; 58 (Suppl. 1): 13-35. (Pubitemid 350022256)
41. Schneeman BO, Burton-Freeman B, Davis P. Incorporating dairy foods into low and high fat diets increases the postprandial cholecystokinin response in men and women. J Nutr 2003; 133: 4124-8. (Pubitemid 37505486)
42. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89: 1070-7. (Pubitemid 16231572)
43. Eberlein GA, Eysselein VE, Schaeffer M, et al. A new molecular form of PYY: structural characterization of human PYY(3-36) and PYY(1-36). Peptides 1989; 10: 797-803. (Pubitemid 19228495)
44. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650-4.
45. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941-8. (Pubitemid 37064767)
46. El Khoury D, El-Rassi R, Azar S, et al. Postprandial ghrelin and PYY responses of male subjects on low carbohydrate meals to varied balancing proportions of proteins and fats. Eur J Nutr 2010; 49: 493-500.
47. Asakawa A, Inui A, Yuzuriha H, et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 2003; 124: 1325-36. (Pubitemid 36531807)
48. Parker RM, Herzog H. Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci 1999; 11: 1431-48. (Pubitemid 29142202)
49. Whitcomb DC, Taylor IL, Vigna SR. Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain. Am J Physiol 1990; 259: G687-91. (Pubitemid 20340481)
50. Kanatani A, Mashiko S, Murai N, et al. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology 2000; 141: 1011-6. (Pubitemid 32260445)
51. Flynn MC, Turrin NP, Plata-Salamán CR, et al. Feeding response to neuropeptide Y-related compounds in rats treated with Y5 receptor antisense or sense phosphothio-oligodeoxynucleotide. Physiol Behav 1999; 66: 881-4. (Pubitemid 29281652)
52. Schmidt PT, Näslund E, Grybäck P, et al. A role for pancreatic polypeptide in the regulation of gastric emptying and short-term metabolic control. J Clin Endocrinol Metab 2005; 90: 5241-6. (Pubitemid 41262281)
53. Jesudason DR, Monteiro MP, McGowan BM, et al. Low-dose pancreatic polypeptide inhibits food intake in man. Br J Nutr 2007; 97: 426-9. (Pubitemid 46662029)
54. Batterham RL, Le Roux CW, Cohen MA, et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003; 88: 3989-92. (Pubitemid 37034556)
55. Clark JT, Kalra PS, Crowley WR, et al. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 1984; 115: 427-9. (Pubitemid 14086844)
56. Malaisse-Lagae F, Carpentier JL, Patel YC, et al. Pancreatic polypeptide: a possible role in the regulation of food intake in the mouse. Hypothesis Experientia 1977; 33: 915-7. (Pubitemid 8128835)
57. Bataille D, Coudray AM, Carlqvist M, et al. Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Isolation of the peptide. FEBS Lett 1982; 146: 73-8. (Pubitemid 13254171)
58. Bataille D, Gespach C, Tatemoto K, et al. Bioactive enteroglucagon (oxyntomodulin): present knowledge on its chemical structure and its biological activities. Peptides 1981; 2 (Suppl. 2): 41-4. (Pubitemid 12118280)
59. Fehmann HC, Jiang J, Schweinfurth J, et al. Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin (9-39). Peptides 1994; 15: 453-6. (Pubitemid 24223320)
60. Druce MR, Minnion JS, Field BC, et al. Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs. Endocrinology 2009; 150: 1712-22.
61. Schjoldager BT, Baldissera FG, Mortensen PE, et al. Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. Eur J Clin Invest 1988; 18: 499-503.
62. Cohen MA, Ellis SM, Le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003; 88: 4696-701. (Pubitemid 37357514)
63. Wynne K, Park AJ, Small CJ, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005; 54: 2390-5. (Pubitemid 41134267)
64. Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 2006; 30: 1729-36. (Pubitemid 44863404)
65. Field BC, Wren AM, Peters V, et al. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010; 59: 1635-9.
66. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287: 199-206.
67. Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 5: 1300-4. (Pubitemid 17156636)
68. Gautier JF, Choukem SP, Gerard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 2008; 34: 65-72.
69. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20: 876-913. (Pubitemid 30647076)
70. Elliott RM, Morgan LM, Tredger JA, et al. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993; 138: 159-66. (Pubitemid 23266831)
71. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-96.
72. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-57. (Pubitemid 46711096)
73. D'Alessio DA, Sandoval Da, Salley RJ. New ways in which GLP-1 can regulate glucosae homeostasis. J Clin Invest 2000; 115: 3406-8. (Pubitemid 43121828)
74. Kanoski SE, Fortin SM, Arnold M, et al. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 2011; 152: 3103-12.
75. Maffeis C, Surano MG, Cordioli S, et al. High-fat vs. a moderate-fat meal in obese boys: nutrient balance, appetite, and gastrointestinal hormone changes. Obesity 2010; 18: 449-55.
76. Choukem SP, Gerard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 2008; 34: 65-72.
77. Karamanlis A, Chaikomin R, Doran S, et al. Effects of protein on glycemic and incretin responses and gastric emptying after oral glucose in healthy subjects. Am J Clin Nutr 2007; 86: 1364-8. (Pubitemid 350126239)
78. UsdinTB, Mezey E, Button DC, et al. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993; 133: 2861-70. (Pubitemid 24000747)
79. McIntosh CH, Pederson RA, Koop H, et al. Gastric inhibitory polypeptide stimulated secretion of somatostatinlike immunoreactivity from the stomach: inhibition by acetylcholine or vagal stimulation. Can J Physiol Pharmacol 1981; 59: 468-72. (Pubitemid 11101651)
80. Meier JJ, Gallwitz B, Siepmann N, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003; 46: 798-801. (Pubitemid 36831408)
81. Lynn FC, Pamir N, Ng EH, et al. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 2001; 50: 1004-11. (Pubitemid 32374530)
82. Gupta D, Peshavaria M, Monga N, et al. Physiologic and pharmacologic modulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta-cells by peroxisome proliferator-activated receptor (PPAR)-gamma signaling: possible mechanism for the GIP resistance in type 2 diabetes. Diabetes 2010; 59: 1445-50.